RECORDATI ANNOUNCES GROWTH IN THE FIRST HALF 2019. REVENUES +6.8%, EBITDA(1) +7.4%, NET INCOME +6.1%

    NEXT STORY
    Immunoassay in R&D Market Value to Surpass USD 7,716.6 Million Revenue Mark by 2023 at 8.18 % CAGR, Says Market Research Future
    PREV STORY
    G1 Therapeutics Appoints Mark Avagliano as Chief Business Officer
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Hopewell Therapeutic Farm Community Receives Extension To Its Nationally Recognized CARF Accreditation

    CLEVELAND, Sept. 29, 2016 (GLOBE NEWSWIRE) -- Hopewell Therapeutic Farm Community has just received ...

    author_avatar
    NASDAQ Market News

    GENFIT: FDA and EMA Grant GENFIT’s Elafibranor Orphan Drug Designation for Primary Biliary Cholangitis (PBC)

    author_avatar
    NASDAQ Market News

    Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

    BOSTON, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company ...

    author_avatar
    NASDAQ Market News